Palatin Technologies Incorporated

Rhythm Pharmaceuticals, Inc.

Rhomed Incorporated

Actinium Pharmaceuticals, Limited

Arizona Board of Regents on Behalf of the University of Arizona

Competitive Technologies, Inc.

Shubh D Sharma

Yi-Qun Shi

Wei Yang

Ramesh Rajpurohit

Zhijun Wu

Annette M Shadiack

Kevin D Burris

Hui-Zhi Cai

Margarita Bastos

Papireddy Purma

Leonardus H T Van Der Ploeg

Bart Henderson

John H Dodd

Xin Chen

Yadi Reddy Bonuga

Kaushik J Dave

Yiqun Shi

Victor J Hruby

Mac E Hadley

Buck A Rhodes

Paul O Zamora

Carl Spana

Lisa E Diamond

Richard J Freer

Bolun Hu

Dennis C Earle

Leonardus HT Van Der Ploeg

The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.

Pharmaceutical compositions

The present invention relates to polypeptide compounds that are modulators (e.g., agonists and antagonists) of the melanocortin-4 receptor (MC4R) and pharmaceutical compositions comprising same. The compounds described herein are polypeptide of the following structural Formula (I): or a pharmaceutically acceptable salt thereof. Values and preferred values of the variables in structural Formula (I) are described herein.

Peptide compositions

Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radio-therapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.

Stabilized radiolabeled anti-CD45 immunoglobulin compositions

Stabilized radio-labeled anti-CD45 immunoglobulin compositions

Melanocortin receptor-specific cyclic peptides of the formula where R, R, R, Rand Rare as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.

Melanocortin receptor-specific peptides

Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radiotherapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.

Melanocortin receptor-specific cyclic peptides of the formula where R, R, R, R, R, R, R, R, R, Rand z are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.

Melanocortin receptor-specific cyclic heptapeptides of the formulaZ-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Y&#x2003;&#x2003;(II)or a pharmaceutically acceptable salt thereof, where Z, Xaa, Xaa, Xaa, Xaa, Xaa, Xaa, Xaaand Y are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.

Melanocortin receptor-specific heptapeptides

Methods for use of a melanocortin receptor agonist cyclic peptide of the formula where R, x and y are as defined in the specification, and compositions and formulations including the peptide of the foregoing formula, for preventing, ameliorating or treating female sexual dysfunction.

Melanocortin receptor-specific peptides for treatment of female sexual dysfunction

Cyclic constructs which bind to a natriuretic peptide receptor and include a plurality of amino acid residues, at least one amino acid surrogate of formula I: where R, R', Q, Y, W, Z, J, x and n are as defined in the specification, and a cyclic linkage including one or two amide bonds, pharmaceutical compositions including such cyclic constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of anti-hypertensive, cardiovascular, renal or endocrine effects are desired.

Amide linkage cyclic natriuretic peptide constructs

Cyclic constructs with an N-terminus and a C-terminus which bind to a natriuretic peptide receptor and include a plurality of amino acid residues, at least one amino acid surrogate of formula I: where R, R', Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group, pharmaceutical compositions including such cyclic constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of anti-hypertensive, cardiovascular, renal or endocrine effects are desired.

Cyclic natriuretic peptide constructs

Growing community of inventors

Cranbury, NJ, United States of America

Shubh D Sharma